Literature DB >> 3467822

Tumor heterogeneity in osteosarcoma as identified by flow cytometry.

W Hiddemann, A Roessner, B Wörmann, W Mellin, B Klockenkemper, T Bösing, T Büchner, E Grundmann.   

Abstract

Measurements of the cellular DNA content by flow cytometry were carried out in 25 untreated osteosarcomas to identify the frequency of DNA aneuploidies and heterogeneous DNA stemlines in relation to histopathology. Analyzing multiple specimens from each single tumor (2-16; median, 4), highly malignant osteosarcomas were found to express DNA aneuploidies in 18 of 21 cases (86%) with multiple aneuploid DNA stemlines in 10 cases (48%). In three paraosteal osteosarcomas, no DNA aneuploidy was detected and a significantly lower proportion of cells in S-phase was observed as compared to the highly malignant osteosarcomas (mean 8.6% vs. 18.8%; P less than 0.05). Like in the paraosteal osteosarcomas, no DNA aneuploidy and a low fraction of cells in S-phase was found in the predominant cell population of one of the very rare sclerosing small cell osteosarcomas, which also revealed a second DNA stemline with a DNA index of 2.0. These results demonstrate a high degree of DNA stemline heterogeneity in highly malignant osteosarcomas. The data emphasize the usefulness of DNA measurements for the characterization of bone tumors and indicate the possibility of discriminating highly malignant from low-grade osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3467822     DOI: 10.1002/1097-0142(19870115)59:2<324::aid-cncr2820590226>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Biological characterization of human bone tumors. X. The proliferation behavior of macrophages as compared to fibroblastic cells in malignant fibrous histiocytoma and giant cell tumor of bone.

Authors:  A Roessner; J Vassallo; E Vollmer; G Zwadlo; C Sorg; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Co-existence of two aneuploid stemlines in benign adenomas. A report of three cases with stemline heterogeneity.

Authors:  H Joensuu; P J Klemi; K A Alanen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

3.  ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.

Authors:  Sarah A Maas; Nina M Donghia; Kathleen Tompkins; Oded Foreman; Kevin D Mills
Journal:  BMC Biol       Date:  2010-10-27       Impact factor: 7.431

4.  Cytostatic effects in osteosarcomas as detected by flow cytometric DNA analysis after preoperative chemotherapy according to the COSS 80/82 protocol.

Authors:  T Bösing; A Roessner; W Hiddemann; W Mellin; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Authors:  Valerie B Sampson; Nancy S Vetter; Wendong Zhang; Pratima U Patil; Robert W Mason; Erika George; Richard Gorlick; Edward A Kolb
Journal:  Oncotarget       Date:  2016-12-27

Review 6.  A Review of T-Cell Related Therapy for Osteosarcoma.

Authors:  Kazushige Yoshida; Masanori Okamoto; Kaoru Aoki; Jun Takahashi; Naoto Saito
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

7.  Establishment and Characterization of New Canine and Feline Osteosarcoma Primary Cell Lines.

Authors:  Florian R L Meyer; Ingrid Walter
Journal:  Vet Sci       Date:  2016-06-01

8.  Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model.

Authors:  Yi Yang; Rui Yang; Michael Roth; Sajida Piperdi; Wendong Zhang; Howard Dorfman; Pulivarthi Rao; Amy Park; Sandeep Tripathi; Carrie Freeman; Yunjia Zhang; Rebecca Sowers; Jeremy Rosenblum; David Geller; Bang Hoang; Jonathan Gill; Richard Gorlick
Journal:  Genes Cancer       Date:  2017-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.